Mesoblast poised to file cell therapy for GVHD in US

Mesoblast poised to file cell therapy for GVHD in US

Source: 
Pharmaforum
snippet: 

Australian biotech Mesoblast can go ahead with a US filing for its off-the-shelf stem cell therapy for acute graft-versus-host disease (GVHD), after negotiations with the FDA.